Edwards LifeSciences
This article was originally published in The Gray Sheet
Executive Summary
Company forecasts during its Dec. 11 analyst day in New York that sales of the Sapien transcatheter heart valve will reach $75 million-$95 million in 2009. Edwards also reaffirms it is on track to start U.S. clinical trials by the end of next year for its next-generation Sapien XT valve. The firm presented early European data on transfemoral delivery of Sapien at the Transcatheter Cardiovascular Therapeutics meeting in October (1"The Gray Sheet" Oct. 20, 2008, p. 16). Edwards' total heart valve therapy business is anticipated to grow 14%-16% in 2009 to $640 million-$670 million. Corporate sales are forecast at $1.24 billion-$1.3 billion
You may also be interested in...
Vying Valves: Edwards’ Sapien Progresses, But CoreValve Remains A Threat
European data for Edwards Lifesciences' Sapien transcatheter heart valve are encouraging, but analysts have raised questions about design of the firm's planned U.S. trial of the device
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.